Pfizer Moving to New Missouri Campus

The company has been located in the state for more than 13 years and currently employs more than 450 scientists and other professionals.
500 Research Drive in St. Charles, Mo., one of Pfizer's current St. Louis-area locations

500 Research Drive in St. Charles, Mo., one of Pfizer’s current St. Louis-area locations

St. Louis—Pfizer Inc. will lease a new $200 million, state-of-the-art production and operations center in Chesterfield, Mo. CRG together with Clayco will be the developer and owner of the new facility.

Pfizer will use the campus to house its bioprocess, analytical and formulation development, non-GMP processing, as well as GMP cell banking operations, and cell bank storage necessary to support both its R&D and commercial biologic and vaccine products.

“Missouri is an important part of Pfizer’s R&D network, and we’re proud of the world-class employee base we’ve built here,” John Ludwig, Pfizer’s senior vice president of biotherapeutics research, said in a prepared release. “Thanks to the support we’ve received from the state of Missouri, St. Louis County and Chesterfield, our new St. Louis laboratory facility will provide the right location and space as we continue to evolve our business over the coming years.”

Pfizer has been located in the state for more than 13 years and currently employs more than 450 scientists and other professionals. This new campus will create another 80 jobs.

The state has offered a strategic economic incentive package that the company can receive if it meets strict job creation criteria. The expansion is also being made possible through local incentives offered by St. Louis County.

“From startups on the brink of discovery to global companies moving the needle on advanced medicine and solutions, Missouri continues to garner expansions and job creation, further solidifying its position as the epicenter of bioscience and tech innovation,” Missouri Governor Jay Nixon said. “Our education and research institutions are shaping the brightest minds that are eager to get into the lab and make a difference in the world. Companies like Pfizer benefit from this growing talent pool and the natural synergy that comes with being part of the region’s burgeoning bioscience community.”

Construction is expected to begin in mid-2017 and be completed by 2020.

Image courtesy of Yardi Matrix